WOCKHARDT LIMITED

The earnings call for Wockhardt Limited on June 4, 2026, featured management discussing the company's transformation and recent achievements, including the US FDA approval of Zaynich, the first Indian research product to receive such approval. Dr. Murtaza Khorakiwala highlighted the company's focus on profitability, reporting a top line of INR 3,373 crores and an EBITDA of INR 630 crores, with a significant increase in EBITDA margin from 5.4% to 18.6% over three years. The company aims to leverage its three business pillars: pharmaceuticals, biosimilars, and novel antibiotics. Management emphasized growth in emerging markets and the importance of operational excellence. The call also included discussions on the launch strategy for Zaynich in the US and India, with a focus on market access and clinical adoption. The leadership team was introduced, showcasing their expertise in the anti-infective space. The session concluded with a Q&A segment addressing various investor inquiries.

Management emphasized significant achievements and growth strategies.